<DOC>
	<DOCNO>NCT00612170</DOCNO>
	<brief_summary>This study investigate effectiveness safety [ S , S ] -Reboxetine relieve symptom Fibromyalgia patient . A previous study demonstrate clinically meaningful treatment effect fibromyalgia , base pain functional endpoint .</brief_summary>
	<brief_title>A 14-week , Multi-center Study S , S-Reboxetine Patients With Fibromyalgia .</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>Male female race , least 18 year age Patients must meet ACR criterion fibromyalgia ( ie , widespread pain present least 3 month , pain least 11 18 specific tender point site ) Patients severe pain ( eg , Diabetic Peripheral Neuropathy PostHerpetic Neuralgia ) may confound assessment self evaluation pain associate fibromyalgia Patients autoimmune rheumatic disorder , nonfocal rheumatic disease ( fibromyalgia ) , active infection , untreated endocrine disorder A current recent diagnosis ( last 6 month ) episode major depressive disorder , dysthymia and/or uncontrolled depression History mania , hypomania , psychotic disorder , current mood disorder psychotic feature</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Phase 3 , safety efficacy study , [ S , S [ -Reboxetine , Fibromyalgia</keyword>
</DOC>